Skip to main content

Table 2 Validity of combinations of breast cancer flags compared with the Cancer Registry, July 2004-December 2008

From: Ascertaining invasive breast cancer cases; the validity of administrative and self-reported data sources in Australia

Breast cancer flags Positive predictive value Sensitivity Specificity
45 and Up Study baseline, Medicare Benefits Schedule and Pharmaceutical Benefits Scheme    
Breast radiotherapy AND dispensed medicine 80.1% 40.3% 99.9%
Breast radiotherapy OR dispensed medicine1 47.9% 82.7% 98.7%
Breast radiotherapy AND self-reported diagnosis 69.3% 36.1% 99.9%
Breast radiotherapy AND dispensed medicine AND self-reported diagnosis2 72.1% 23.9% 99.9%
(Breast radiotherapy OR dispensed medicine) AND self-reported diagnosis 58.6% 60.4% 99.8%
Breast radiotherapy OR dispensed medicine OR self-reported diagnosis 27.0% 95.3% 97.7%
Admitted Patients Data Collection, 45 and Up Study baseline, Medicare Benefits Schedule and Pharmaceutical Benefits Scheme    
(Lumpectomy or mastectomy) AND diagnosis of invasive breast cancer AND breast radiotherapy 90.1% 47.5% 99.9%
(Lumpectomy or mastectomy) AND diagnosis of invasive breast cancer AND breast radiotherapy AND dispensed medicine 89.7% 33.7% 99.9%
(Lumpectomy or mastectomy) AND diagnosis of invasive breast cancer AND dispensed medicine 87.8% 55.0% 99.9%
(Lumpectomy or mastectomy) AND (diagnosis of invasive breast cancer OR breast radiotherapy) 83.0% 83.2% 99.8%
(Lumpectomy or mastectomy) AND (diagnosis of invasive breast cancer OR dispensed medicine) 84.1% 83.1% 99.8%
(Lumpectomy or mastectomy) AND (diagnosis of invasive breast cancer OR breast radiotherapy OR dispensed medicine) 80.5% 83.6% 99.7%
(Lumpectomy or mastectomy) AND diagnosis of invasive breast cancer AND self-reported diagnosis 88.5% 71.1% 99.9%
(Lumpectomy or mastectomy) AND diagnosis of invasive breast cancer AND breast radiotherapy AND self-reported diagnosis 87.3% 29.4% 99.9%
  1. 1: Tamoxifen, toremifene, anastrozole, exemestane, letrozole, goserelin, trastuzumab, lapatinib, and medroxyprogesterone 500 mg.
  2. 2: Flag combinations including self-reported diagnosis of breast cancer were compared against the Cancer Registry for the period July 2004 to December 2005.